Sector: Basic Materials | Industry: Specialty Chemicals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 5 Paragon Drive MONTVALE NJ 07645 |
Tel: | N/A |
Website: | https://balchem.com |
IR: | See website |
Key People | ||
Theodore L. Harris Chairman of the Board, President, Chief Executive Officer | Martin Bengtsson Chief Financial Officer, Executive Vice President | M. Brent Tignor Chief Human Resource Officer, Senior Vice President |
Hatsuki Miyata Executive Vice President, General Counsel, Secretary | Michael R. Sestrick Senior Vice President, Chief Technology Officer | Frederic Boned Senior Vice President, General Manager - Human Nutrition and Health |
Job L. Van Gunsteren Senior Vice President, General Manager - Specialty Products | Jonathan H. Griffin Senior Vice President - Corporate Development | Martin L. Reid Senior Vice President, Chief Supply Chain Officer |
Business Overview |
Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. The Company's segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. Through Specialty Products, it re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia. |
Financial Overview |
For the three months ended 31 March 2024, Balchem Corp revenues increased 3% to $239.7M. Net income increased 28% to $29M. Revenues reflect Human nutrition & health segment increase of 15% to $152.7M, United States segment increase of 9% to $182.1M. Net income benefited from Other expense - Balancing value increase of 67% to $693K (income), Interest expense - Balancing value decrease of 3% to $5.4M (expense). |
Employees: | 1,302 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $5,315M as of Mar 31, 2024 |
Annual revenue (TTM): | $929.56M as of Mar 31, 2024 |
EBITDA (TTM): | $217.76M as of Mar 31, 2024 |
Net annual income (TTM): | $114.82M as of Mar 31, 2024 |
Free cash flow (TTM): | $121.67M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | $243.38M as of Mar 31, 2024 |
Shares outstanding: | 32,423,468 as of Apr 22, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |